129 related articles for article (PubMed ID: 21512394)
61. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
Shen WC; Yang TS; Hsu HC; Chen JS
Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
[TBL] [Abstract][Full Text] [Related]
62. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Comella P; Lorusso V; Maiorino L; Casaretti R; Cannone M; Massidda B; Putzu C; Leo S; Roselli M; Mancarella S; Palmeri S; Greco E; Vessia G; Sandomenico C; Franco L
Cancer Chemother Pharmacol; 2009 Oct; 64(5):893-9. PubMed ID: 19189106
[TBL] [Abstract][Full Text] [Related]
63. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
64. Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
Hirao K; Hirasaki S; Tsuzuki T; Kajiwara T; Hyodo I
Intern Med; 2004 Feb; 43(2):106-10. PubMed ID: 15005251
[TBL] [Abstract][Full Text] [Related]
65. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Chon HJ; Rha SY; Park HS; Shin SJ; Kim HS; Roh JK; Noh SH; Chung HC; Jeung HC
Cancer Chemother Pharmacol; 2011 Oct; 68(4):991-9. PubMed ID: 21327684
[TBL] [Abstract][Full Text] [Related]
66. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Iwanaga I; Kudo M; Tateyama M; Meguro T; Uebayashi M; Saga A; Sakata Y; Asaka M
Oncology; 2011; 80(1-2):70-5. PubMed ID: 21659785
[TBL] [Abstract][Full Text] [Related]
67. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
Ishiguro H; Saji S; Nomura S; Tanaka S; Ueno T; Onoue M; Iwata H; Yamanaka T; Sasaki Y; Toi M
Cancer Med; 2017 Dec; 6(12):2909-2917. PubMed ID: 29131533
[TBL] [Abstract][Full Text] [Related]
68. [Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].
Miura T; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Takahashi T
Gan To Kagaku Ryoho; 2010 Jan; 37(1):77-81. PubMed ID: 20087036
[TBL] [Abstract][Full Text] [Related]
69. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
70. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Zeng C; Zhou H; Wei Y; Wang L; Xie H; Yao W
Chin Med J (Engl); 2014; 127(5):951-6. PubMed ID: 24571893
[TBL] [Abstract][Full Text] [Related]
71. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
72. Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Das K; Taguri M; Imamura H; Sugimoto N; Nishikawa K; Yoshida K; Tan P; Tsuburaya A
Cancer Lett; 2018 Jan; 412():208-215. PubMed ID: 29061504
[TBL] [Abstract][Full Text] [Related]
73. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Jeung HC; Rha SY; Cho BC; Yoo NC; Roh JK; Roh WJ; Chung HC; Ahn JB
Br J Cancer; 2006 Dec; 95(12):1637-41. PubMed ID: 17106441
[TBL] [Abstract][Full Text] [Related]
74. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
75. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
[TBL] [Abstract][Full Text] [Related]
76. [Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Hibi S; Ina K; Furuta R; Kataoka T; Kojima S; Kawai M
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1485-8. PubMed ID: 19755817
[TBL] [Abstract][Full Text] [Related]
77. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
[TBL] [Abstract][Full Text] [Related]
78. [Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Nakadaira K; Kurosaki I; Ueki H
Gan To Kagaku Ryoho; 2008 May; 35(5):837-9. PubMed ID: 18487925
[TBL] [Abstract][Full Text] [Related]
79. CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).
Mochizuki Y; Ohashi N; Kojima H; Ishigure K; Kinoshita T; Eguchi T; Fujitake S; Ito S; Fujiwara M; Kodera Y
Cancer Chemother Pharmacol; 2013 Sep; 72(3):629-35. PubMed ID: 23881212
[TBL] [Abstract][Full Text] [Related]
80. Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Naitoh H; Yamamoto H; Murata S; Kobayashi H; Inoue K; Tani T
Gastric Cancer; 2014 Oct; 17(4):630-7. PubMed ID: 24318670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
